Skye Bioscience, Inc. cash flow to debt ratio of -15.74K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Skye Bioscience, Inc.'s free cash flow has decreased 60.46% from $-26.84M last year to $-43.07M, signaling decreasing performance

Skye Bioscience, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability.

Skye Bioscience, Inc.'s debt has increased relative to shareholder equity from 0.01 last year to 0.03 today, signaling weakened financials

Skye Bioscience, Inc. has a net cash position, so leverage is healthy.

Skye Bioscience, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Skye Bioscience, Inc. has insufficient data to evaluate this check.

Skye Bioscience, Inc.'s short-term assets of $27.09M exceed its short-term liabilities of $8.21M

Skye Bioscience, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Skye Bioscience, Inc.'s return on equity of -217.27%, is lower than 15.00%, indicating bad performance

Skye Bioscience, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Skye Bioscience, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Skye Bioscience, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Skye Bioscience, Inc. has negative free cash flow, indicating cash burn

Skye Bioscience, Inc.'s yearly earnings has decreased 110.50% since last year from $-26.57M to $-55.92M, signaling decreasing performance

Skye Bioscience, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -633.68% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Skye Bioscience, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Skye Bioscience, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Skye Bioscience, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Skye Bioscience, Inc. has insufficient data to evaluate this check.

Skye Bioscience, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Skye Bioscience, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Skye Bioscience, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Skye Bioscience, Inc. has insufficient data to evaluate this check.

Skye Bioscience, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Skye Bioscience, Inc. has a price-to-book ratio of 2.34x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Skye Bioscience, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue